Manuel L Gonzalez1, Reza Alaghehbandan2, Krystina Pivovarcikova3, Kvetoslava Michalova3, Joanna Rogala4, Petr Martinek3, María P Foix5, Enric C Mundo5, Eva Comperat6, Monika Ulamec7, Milan Hora8, Michal Michal3, Ondrej Hes3. 1. Department of Pathology, University of Kansas, Medical Center, Kansas City, Kansas, USA. 2. Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada. 3. Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic. 4. Department of Pathology, University Hospital Wroclaw, Wroclaw, Poland. 5. Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain. 6. Department of Pathology, Hospital Tenon, Paris, Sorbonne University, Paris, France. 7. 'Ljudevit Jurak' Pathology Department, Clinical Hospital Center 'Sestre milosrdnice', Pathology Department, Medical University, Medical Faculty Zagreb, Zagreb, Croatia. 8. Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.
Abstract
AIMS: Current available data on cytokeratin 7 (CK7) immunostaining pattern in the clear cell renal cell carcinoma (RCC) spectrum is conflicting. The aim of this study was to assess CK7 immunoreactivity within the spectrum of clear cell renal neoplasms, including clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like tumours. METHODS AND RESULTS: We analysed two clones of CK7 and two tumour blocks for a total of 75 cases divided into five distinct groups: (i) low-grade clear cell RCC, (ii) high-grade clear cell RCC, (iii) multicystic renal neoplasm of low malignant potential, (iv) clear cell RCC with cystic changes and (v) clear cell papillary RCC-like tumours. We found the highest CK7 reactivity in low-grade clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like groups, ranging from 60% to 93%. CONCLUSIONS: Our findings show that CK7 immunoreactivity in clear cell RCC is variable, and the extent of staining depends on the grade and architectural growth patterns of the tumours.
AIMS: Current available data on cytokeratin 7 (CK7) immunostaining pattern in the clear cell renal cell carcinoma (RCC) spectrum is conflicting. The aim of this study was to assess CK7 immunoreactivity within the spectrum of clear cell renal neoplasms, including clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like tumours. METHODS AND RESULTS: We analysed two clones of CK7 and two tumour blocks for a total of 75 cases divided into five distinct groups: (i) low-grade clear cell RCC, (ii) high-grade clear cell RCC, (iii) multicystic renal neoplasm of low malignant potential, (iv) clear cell RCC with cystic changes and (v) clear cell papillary RCC-like tumours. We found the highest CK7 reactivity in low-grade clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like groups, ranging from 60% to 93%. CONCLUSIONS: Our findings show that CK7 immunoreactivity in clear cell RCC is variable, and the extent of staining depends on the grade and architectural growth patterns of the tumours.
Authors: Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou Journal: Mod Pathol Date: 2021-03-04 Impact factor: 8.209
Authors: Kristyna Prochazkova; Nikola Ptakova; Reza Alaghehbandan; Sean R Williamson; Tomáš Vaněček; Josef Vodicka; Vladislav Treska; Joanna Rogala; Kristyna Pivovarcikova; Kvetoslava Michalova; Maryna Slisarenko; Milan Hora; Michal Michal; Ondrej Hes Journal: Cancers (Basel) Date: 2021-11-24 Impact factor: 6.639